Gain Therapeutics
GANX
26 hedge funds and large institutions have $7.04M invested in Gain Therapeutics in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
42% more call options, than puts
Call options by funds: $85K | Put options by funds: $60K
40% more capital invested
Capital invested by funds: $5.05M → $7.04M (+$1.99M)
8% more funds holding
Funds holding: 24 → 26 (+2)
1.58% more ownership
Funds ownership: 7.55% → 9.13% (+1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$979K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$200K |
| 3 |
BlackRock
New York
|
+$198K |
| 4 |
Millennium Management
New York
|
+$131K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$128K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$254K |
| 2 |
PCM
Prelude Capital Management
New York
|
-$92.4K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$66.7K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$51.9K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$37.4K |
GANX Hedge Fund Activity: Q1 2024 in Review
26 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q1 2024, worth a combined $7.04M — up 40% from $5.05M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new GANX positions and 3 closed out — a net gain of 3 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was Raymond James & Associates, adding an estimated $979K. The largest seller was Citadel Advisors, cutting an estimated $254K.
- 26 institutional investors held Gain Therapeutics (GANX) as of Q1 2024, up from 24 in Q4 2023.
- Funds reported $7.04M of Gain Therapeutics stock for Q1 2024, up 40% quarter-over-quarter.
- 6 funds opened new Gain Therapeutics positions in Q1 2024 and 3 closed out, a net change of +3 holders.
- The largest Gain Therapeutics buyer in Q1 2024 was Raymond James & Associates, an estimated $979K added.
- The largest Gain Therapeutics seller in Q1 2024 was Citadel Advisors, an estimated $254K sold.
Based on aggregated 13F filings for Q1 2024.